Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Substudy of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis
Sponsor: Eli Lilly and Company
Summary
The main purpose of this study is to assess the long-term safety and tolerability of LY4256984 in participants with Amyotrophic Lateral Sclerosis (ALS). This study is a long-term extension of study J6I-MC-OWAA (NCT07100119) and is part of the OLMP (NCT07571200) master protocol that will last approximately 96 weeks.
Official title: A Study of Long-Term Safety, Tolerability, and Clinical Outcomes of Intrathecally Administered LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis: A Multicenter, Open-Label, Long-Term Extension of Study J6I-MC-OWAA
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
32
Start Date
2026-05-14
Completion Date
2029-06
Last Updated
2026-07-17
Healthy Volunteers
No
Conditions
Interventions
LY4256984
Administered IT
Locations (10)
UZ Leuven
Leuven, Belgium
University Hospital - London Health Sciences Centre
London, Canada
McGill University Health Centre
Montreal, Canada
Sunnybrook Research Institute
Toronto, Canada
Universitätsklinikum Schleswig-Holstein
Lübeck, Germany
Universitätsmedizin Rostock
Rostock, Germany
Universitaetsklinikum Ulm
Ulm, Germany
Universitair Medisch Centrum Utrecht
Utrecht, Netherlands
Hospital Universitari de Bellvitge
L'Hospitalet de Llobregat, Spain
Hospital Universitari i Politecnic La Fe
Valencia, Spain